伏立康唑在老年人肺内的稳态浓度被引量：1

下载PDF

导出

摘要目的:观察伏立康唑在老年人肺内的稳态浓度。方法:20例进行支气管镜检查的老年人,应用伏立康唑(6mg/kg)静脉应用,12小时1次,共2次;此后改为口服,200mg,2次/日,连续4周。分别于用药后1、2、4周时进行支气管灌流洗(Bronchoalveolar lavage,BAL),同时采集静脉血标本。分别检测药物在血浆、上皮衬液、肺泡巨细胞内的稳态浓度。结果:药物浓度在巨细胞中最高,上皮衬液中次之,血浆中最低。结论:伏立康唑在肺内浓度高于血浆药物浓度。

作者贺卫国

机构地区河南鹤壁煤业公司总医院

出处《中国社区医师（医学专业）》 2011年第23期39-39,共1页

关键词伏立康唑药物分布稳态

分类号 R311 [医药卫生—基础医学]

引文网络
相关文献

参考文献5

1史煜波,李苏娅,金宁宁.伏立康唑和氟康唑对酵母菌的抗菌活性分析[J].现代实用医学,2006,18(12):870-871. 被引量：6
2Lehneman,J.B.,G.A.Smallwood,et al.Review of patient outcomes of Aspergillus prophylaxis with voriconazole after transplantation.J.Heart Lung Transpl,2005,24(Suppl.1):S169.6.
3Capitano B,H.M.Mattoes,E.Shore,et al.Steady-state intrapulmonary concentrations of moxifloxacin,levofloxacin and azithromycin in older adults.Chest,2004,125:965-973.
4沈海蓉,李中东,钟明康.新型抗真菌药伏立康唑[J].中国新药与临床杂志,2004,23(5):308-310. 被引量：39
5Husain,S.,D.B.Zaldonis,E.J.Kwak,et al.Role of voriconazole prophylaxis for the prevention of invasive aspergillosis (IA) at six months in lung transplant recipients.J.Heart Lung Transpl,2004,23(Suppl.1):S110.

二级参考文献20

1GHANNOUM MA,KUHN DM.Voriconazole-better chances for patients with invasive mycoses[J].Eur J Med Res,2002,7 (5) :242-256.
2PFALLER MA,DIEKEMA DJ,JONES RN,et al. International surveillance of bloodstream infections due to Candida species:frequency of occurrence and in vitro susceptibilities to fluconazole,ravuconazole,and voriconazole of isolates collected from 1997 through 19
3ESPINEL-INGROFF A.In vitro activity of the new triazole voriconazole(UK-109,496)against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens[J].J Clin Microbiol, 1998,36 ( 1 ) :198-202.
4ESPINEL-INGROFF A.In vitro fungicidal activities of voriconazole,itraconazole,and amphotericin B against opportunistic moniliaceous and dematiaceous fungi[J].J Clin MicrobioI,2001,39 (3) :954-958.
5CARRILLO AJ,GUARRO J.In vitro activities of four novel triazoles against Scedosporium spp[J].Antimicrob Agents Chemother, 2001,45 ( 7 ) :2151-2153.
6PURKINS L,WOOD N,GHAHRAMANI P, et al. Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens[J].Antimicrob Agents Chemother, 2002,46 (8) :2546-2553.
7VENKATARAMANAN R, ZANG S,GAYOWSKI T, et al. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes[J].Antimicrob Agents Chemother,2002,46 (9) :3091-3093.
8ROMERO A J, POGAMP PL,NILSSON LG, et al. Effect of voriconazole on the pharmacokinetics of cycrosporine in renal transplant patients[J].J Clin Pharmacol Ther,2002,71 (4) :226-234.
9DENNING DW, RIBAUD P, MILPIED N,et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis[J].Clin Infect Dis,2002,34 (5) :563-571.
10HEBRECHT R,DENNING DW, PATTERSON TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis[J].N Engl J Med,2002,347 (6) :408-415.